Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for DIVISLAB.NS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DIVISLAB.NS and 80,000+ other tickers.
See exactly how DIVISLAB.NS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DIVISLAB.NS and 80,000+ other tickers.
Divi's Laboratories Limited, established in 1990 and based in Hyderabad, India, operates globally in the production and distribution of generic active pharmaceutical ingredients (APIs), intermediate chemicals, and nutraceuticals. The company's market footprint encompasses India, the United States, Asia, Europe, and other international regions. In addition to its core product lines, Divi's offers bespoke synthesis services for APIs and intermediates. It also provides a diverse range of carotenoids and markets various vitamins, catering to the nutritional, pharmaceutical, food and beverage, and…
No recent news available.